NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
August 27, 2024 — InMed Pharmaceuticals announces promising outcomes from a long-term preclinical study of its Alzheimer’s Disease drug candidate, INM-901, confirming and expanding upon previous results.
August 27, 2024 — Benchmark International releases latest insights on 2024 hospital and health system M&A landscape, revealing robust activity and diverse motivations driving transactions.
August 27, 2024 — SaveRxCanada.to is addressing the crisis of unaffordable medication costs for American seniors by connecting them with licensed Canadian pharmacies, offering significant savings on essential medications without compromising safety or quality.
August 26, 2024 — Minerva Surgical introduces Symphion Fluid Deficit Readout to enhance patient safety and procedural precision during operative hysteroscopy procedures. The launch reflects the company's commitment to advancing gynecologic surgery.
August 26, 2024 — Theriva Biologics receives Rare Pediatric Drug Designation for VCN-01, a treatment for retinoblastoma, from the FDA. This signifies an important step forward in addressing the high unmet need for effective treatments for childhood cancer.
August 26, 2024 — Glucotrack Inc. is transforming diabetes management with its innovative Continuous Blood Glucose Monitor (CBGM) device, set to revolutionize the continuous glucose monitoring market. With groundbreaking research, secured funding, and upcoming human clinical trials, Glucotrack's technology could greatly impact the lives of people with diabetes.
August 26, 2024 — Research reveals higher risk of mental illness in individuals diagnosed with unruptured cerebral aneurysms, emphasizing the need for targeted mental health support and comprehensive care.
August 26, 2024 — Unsilenced Impact app released to empower survivors and allies in the fight against institutional child abuse within the Troubled Teen Industry
August 25, 2024 — CD BioSciences introduces high-quality, cost-effective C. elegans pharyngeal pumping analysis services for drug screening, leveraging the power of C. elegans to provide valuable insights into potential drug candidates' effects.
August 25, 2024 — TexasPlans.com releases comprehensive guide on major medical insurance options in Texas, offering practical advice and personalized assistance for individuals and families to make informed decisions about health coverage.
August 25, 2024 — SaveRxCanada.to voices concern over the potential implications of Project 2025's proposed changes to Medicare's prescription drug plan, warning that these changes could increase drug costs for millions of seniors and other Medicare beneficiaries.
August 24, 2024 — SaveRxCanada.to is proud to offer affordable access to a wide range of generic prescription drugs for Americans looking to save money on their medication costs. With prices significantly lower than those found in the United States, customers can find relief from high prescription drug prices by choosing SaveRxCanada.to for their medication needs.
August 23, 2024 — CNS Pharmaceuticals, a biopharmaceutical company, to be spotlighted in Virtual Investor CEO Connect with CEO John Climaco participating in live webcast. Berubicin, their lead drug candidate, is in development for brain and CNS cancers.
August 23, 2024 — Positive results of two Phase 2 clinical trials for a new ALS treatment, CNM-Au8, show significant improvement in biomarkers. CEO expresses optimism about the potential breakthrough.
August 23, 2024 — Clene (NASDAQ: CLNN) announces positive Phase 2 ALS trial results for CNM-Au8, showing significant improvement in biomarkers. CEO expresses optimism about the potential of CNM-Au8 as a new treatment for ALS.
August 23, 2024 — RedHill Biopharma's opaganib shows promise in diabetes and obesity treatment, while the commercialization of Talicia for Helicobacter pylori offers potential new therapies. Exciting developments from RedHill Biopharma.
August 23, 2024 — Discover how diagnostic companies like Exact Sciences, Guardant Health, Illumina, and Ludwig Enterprises are thriving after the pandemic fallout. Learn about early cancer screening tests and potential investment opportunities.
August 23, 2024 — Cutting-edge study enhances streamflow prediction with transfer learning, presenting a transformative tool for water resource management and climate change mitigation.
August 22, 2024 — Scinai Immunotherapeutics closes loan restructuring agreement with the European Investment Bank, converting a significant loan amount into preferred shares. This development signals positive financial stability and future growth for the company.
August 21, 2024 — Scinai Immunotherapeutics (NASDAQ: SCNI) enters into a $2 million Investment Commitment Agreement with RK Stone Miami LLC, demonstrating the company's dedication to developing inflammation and immunology biological products and providing CDMO services.